Free Trial

Synlogic (SYBX) Stock Price, News & Analysis

Synlogic logo
$1.26 -0.02 (-1.17%)
As of 02:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Synlogic Stock (NASDAQ:SYBX)

Key Stats

Today's Range
$1.20
$1.28
50-Day Range
$1.20
$1.45
52-Week Range
$1.15
$1.96
Volume
11,280 shs
Average Volume
20,749 shs
Market Capitalization
$14.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

Remove Ads

Synlogic Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
36th Percentile Overall Score

SYBX MarketRank™: 

Synlogic scored higher than 36% of companies evaluated by MarketBeat, and ranked 765th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Synlogic.

  • Earnings Growth

    Earnings for Synlogic are expected to grow in the coming year, from ($2.71) to ($0.47) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Synlogic is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Synlogic is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Synlogic has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Synlogic's valuation and earnings.
  • Percentage of Shares Shorted

    0.74% of the float of Synlogic has been sold short.
  • Short Interest Ratio / Days to Cover

    Synlogic has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Synlogic has recently increased by 3.48%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Synlogic does not currently pay a dividend.

  • Dividend Growth

    Synlogic does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.74% of the float of Synlogic has been sold short.
  • Short Interest Ratio / Days to Cover

    Synlogic has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Synlogic has recently increased by 3.48%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Synlogic has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Synlogic this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Synlogic insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,802.00 in company stock.

  • Percentage Held by Insiders

    Only 3.02% of the stock of Synlogic is held by insiders.

  • Percentage Held by Institutions

    63.40% of the stock of Synlogic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Synlogic's insider trading history.
Receive SYBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synlogic and its competitors with MarketBeat's FREE daily newsletter.

SYBX Stock News Headlines

Synlogic Reports Q3 2024 Financial Outcomes
Why Buffett and 100 members of Congress are Piling into this One Investment
While everyone's distracted by the recent stock market rally and Trump's tariffs... There's a much bigger story that's flying under the radar for now: Why are Warren Buffett, Ken Griffin, Roman Abramovich, the Koch Brothers, Carlos Slim and at least 100 members of Congress all going against "conventional wisdom?" And why are they all piling into ONE overlooked corner of the stock market? It's not crypto... gold... or options strategies.
Synlogic Reports Third Quarter 2024 Financial Results
Synlogic, Inc. (0A8U.L)
MIN.SG,0P0001I7V6,0 (MIN.SG)
See More Headlines

SYBX Stock Analysis - Frequently Asked Questions

Synlogic's stock was trading at $1.40 at the beginning of the year. Since then, SYBX stock has decreased by 9.6% and is now trading at $1.2650.
View the best growth stocks for 2025 here
.

Synlogic, Inc. (NASDAQ:SYBX) issued its quarterly earnings results on Thursday, March, 6th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.04.

Shares of Synlogic reverse split on the morning of Thursday, September 28th 2023. The 1-15 reverse split was announced on Thursday, September 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Synlogic's top institutional shareholders include Renaissance Technologies LLC (0.19%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Antoine Awad, Aoife Brennan, Mary Beth Dooley and Michael Vangsted Jensen.
View institutional ownership trends
.

Shares of SYBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Synlogic investors own include Reata Pharmaceuticals (RETA), Sangamo Therapeutics (SGMO), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE) and Exelixis (EXEL).

Company Calendar

Last Earnings
3/06/2025
Today
3/31/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SYBX
Employees
80
Year Founded
2013

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-57,280,000.00
Pretax Margin
-1,591.50%

Debt

Sales & Book Value

Annual Sales
$8,000.00
Price / Cash Flow
N/A
Book Value
$4.64 per share
Price / Book
0.27

Miscellaneous

Free Float
11,343,000
Market Cap
$14.80 million
Optionable
Optionable
Beta
0.72

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:SYBX) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners